Testosterone Replacement Therapy (TRT)

Testosterone replacement therapy is clinician-supervised treatment for men with symptomatic, confirmed androgen deficiency. Benefits and risks depend on the diagnosis being real, the formulation matching the person, and the program monitoring fertility, hematocrit, prostate, and cardiovascular risk against an honest dose target.

Also known as: TRT, testosterone therapy, androgen replacement therapy, low-T treatment

Context

Few interventions in men’s health are as polarized as testosterone therapy. The same vial or gel can be replacement medicine for a man with a real endocrine diagnosis, performance-enhancing pharmacology for an athlete, or the centerpiece of a vague vitality program. Those are not the same clinical act, and the surrounding pressures, marketing, fertility considerations, and risk profiles are not the same either.

In the United States, FDA-approved testosterone products are approved for men who have low testosterone in conjunction with an associated medical condition, such as testicular failure, pituitary or hypothalamic disease, genetic syndromes, chemotherapy injury, or other defined causes. They are not approved as general therapy for healthy men whose testosterone has declined with age. In April 2026, the FDA invited sponsors to discuss a possible supplemental indication for low libido in men with idiopathic hypogonadism, meaning low testosterone where no underlying cause has been identified. That is a regulatory opening, not a blanket approval.

The longevity audience usually hears about TRT through a different channel: men’s health clinics, telemedicine prescribers, podcasts, and friends who report better libido, mood, or training drive. The question is not whether some men feel better on testosterone. Some clearly do. The real question is whether the person has a diagnosis that justifies replacement, whether the expected benefit matches the evidence, and whether the program keeps testosterone inside physiologic replacement rather than drifting into supraphysiologic use.

Problem

Low testosterone symptoms are real but nonspecific. Low libido, erectile dysfunction, fatigue, low mood, anemia, falling bone density, lost muscle, and poor training recovery can all signal androgen deficiency. They can equally well signal sleep apnea, obesity, depression, overtraining, undernutrition, heavy alcohol use, opioid or glucocorticoid exposure, thyroid disease, or ordinary poor sleep — none of which testosterone fixes.

That ambiguity creates two bad frames. One dismisses symptomatic men because “low T” has been overmarketed. The other treats any disappointing lab value as proof that a man needs testosterone. A single afternoon total-testosterone result near the lower reference range can become a lifelong prescription before anyone checks whether the value was real, whether the sex hormone-binding globulin is distorting it, whether fertility plans should change the path, or whether obesity, sleep apnea, alcohol, or opioids are doing the actual work.

TRT fails when diagnosis is loose and dose becomes identity. It works best when it is boring: clear criteria, morning repeat labs, a reason for the low value, physiologic target range, adverse-effect monitoring, and a willingness to stop when the clinical signal is poor.

Forces

• Symptoms matter, but symptoms alone do not diagnose androgen deficiency.
• Total testosterone is easy to order, but timing, assay quality, sex hormone-binding globulin, illness, sleep, and recent behavior can change the result.
• TRT can improve sexual symptoms, anemia, bone density, lean mass, and mood in some hypogonadal men, but it isn’t a proven healthy-adult longevity drug.
• Exogenous testosterone can suppress spermatogenesis, so fertility goals change the treatment path.
• Cardiovascular and prostate concerns are more specific after TRAVERSE, but “no MACE excess in one trial population” is not the same as universal safety.
• The clinic market rewards fast access and high-normal numbers, while good medicine rewards candidate selection and monitoring.

Solution

Treat TRT as replacement therapy for confirmed androgen deficiency, not as a generic optimization protocol. The responsible version begins with diagnosis. Current major guidelines require symptoms or signs consistent with testosterone deficiency plus consistently low morning testosterone. The American Urological Association uses total testosterone below 300 ng/dL as a reasonable cutoff in support of diagnosis, but it also requires two early-morning measurements on separate occasions and compatible symptoms. The Endocrine Society similarly requires symptoms plus unequivocally and consistently low total testosterone, with free testosterone measured when total testosterone is borderline or sex hormone-binding globulin may distort the picture.

The next step is cause. A clinician distinguishes primary hypogonadism, where the testes fail to produce adequate testosterone, from secondary hypogonadism, where hypothalamic or pituitary signaling is impaired. Luteinizing hormone and follicle-stimulating hormone help make that distinction. Reversible contributors also matter. Obesity, sleep apnea, undernutrition, opioids and glucocorticoids, anabolic-steroid withdrawal, hyperprolactinemia, and pituitary disease can each suppress the axis. Treating one of those changes the interpretation, and sometimes the need to prescribe at all.

Candidate selection is narrowest when fertility is near-term. Exogenous testosterone can suppress luteinizing hormone and follicle-stimulating hormone, which can suppress sperm production. A man trying to conceive, or trying to preserve near-term fertility, usually needs a reproductive-urology discussion before any testosterone prescription. Alternatives such as selective estrogen receptor modulators or gonadotropin-based approaches may be considered by specialists in some cases, but those are different clinical pathways.

For men who are candidates, the target is physiologic replacement, usually mid-normal testosterone concentrations, not the highest number a lab range will tolerate. Formulation is a medical decision. Gels, injections, patches, oral testosterone undecanoate, and pellets differ in pharmacokinetics, transfer risk, blood-pressure signal, peak-trough pattern, erythrocytosis risk, convenience, and cost; a good program explains why the chosen one fits the person’s diagnosis and constraints rather than the prescriber’s habits.

Monitoring is part of the intervention. A clinician tracks the original symptom target, testosterone at the right point in the dosing cycle, hematocrit, blood pressure, prostate-specific antigen where appropriate, and the predictable adverse-effect surface: acne, edema, mood, sleep apnea, fertility, and partner or child exposure to transferred gel. If the program can’t state what would cause dose reduction, pause, referral, or discontinuation, it isn’t a medical protocol. It is access.

Evidence

Evidence tier: RCT (human) for symptom and safety outcomes in symptomatic hypogonadal men; no human RCT evidence that TRT extends lifespan in healthy men.

The Testosterone Trials are the clearest efficacy reference for older symptomatic men. In 790 men at least 65 years old with testosterone below 275 ng/dL and symptoms, testosterone gel for one year improved sexual activity, sexual desire, and erectile function. It produced some benefit in mood and depressive symptoms, but did not improve vitality or the primary walking-distance outcome. That is a useful signal, but it is narrower than the public story. The strongest benefit was sexual function, not broad performance restoration.

TRAVERSE changed the cardiovascular conversation. The trial randomized 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting morning testosterone values below 300 ng/dL, and preexisting or high risk of cardiovascular disease to testosterone gel or placebo. Major adverse cardiovascular events occurred in 7.0% of the testosterone group and 7.3% of the placebo group; the hazard ratio was 0.96 with a 95% confidence interval of 0.78 to 1.17. That supported noninferiority for the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in this trial population.

The safety story did not end there. TRAVERSE reported higher rates of atrial fibrillation, nonfatal arrhythmia requiring intervention, acute kidney injury, and pulmonary embolism in the testosterone group. A fracture substudy later found more clinical fractures among testosterone-treated men than placebo-treated men, despite prior evidence that testosterone can improve bone density. Those findings do not make TRT categorically unsafe. They do make the monitoring and candidate boundary real.

The prostate signal is also more specific than old arguments allowed. A 2023 JAMA Network Open analysis of prostate outcomes inside TRAVERSE found low rates of high-grade prostate cancer, any prostate cancer, acute urinary retention, invasive prostate procedures, and new lower-urinary-tract medication, with no significant difference between testosterone and placebo. But those men were screened carefully: men with prior prostate cancer, high PSA, severe lower urinary tract symptoms, or prostate abnormality were excluded. The evidence supports reassurance in a screened population, not casual use in unscreened men.

Regulators have shifted with the evidence. In February 2025, the FDA removed boxed-warning language on adverse cardiovascular outcomes after reviewing TRAVERSE, while retaining limitation-of-use language for age-related hypogonadism and adding class-wide blood-pressure warnings. In April 2026, the agency took an initial step toward possible expanded labeling for low libido in idiopathic hypogonadism, emphasizing that any new indication would still require substantial evidence of effectiveness and a favorable benefit-risk balance.

How It Plays Out

A 54-year-old with low libido, low morning erections, anemia, and two early-morning testosterone levels under 300 ng/dL sees a urologist. The next useful step is not an online dose table. It is cause-finding, fertility discussion, baseline hematocrit and prostate review, formulation choice, and a symptom target. If libido and anemia improve and hematocrit stays controlled, the program has a measurable rationale.

A 47-year-old with a single low afternoon testosterone result, untreated sleep apnea, heavy alcohol use, and no repeat morning test is a different case. TRT might still be discussed later, but the first job is to clean up diagnosis. Treating the number before treating sleep, alcohol, weight, medications, and timing can convert a reversible physiology problem into chronic pharmacology.

A 38-year-old trying to conceive is not an ordinary TRT candidate. Exogenous testosterone may make symptoms better while making sperm production worse. In that setting, reproductive goals are not a footnote. They’re the central constraint, and a reproductive urologist may take the case in a different direction.

A clinic pushes testosterone, thyroid hormone, growth-hormone secretagogues, and peptides under one “male optimization” package. The quality test is simple: each drug needs its own diagnosis, evidence tier, regulatory status, monitoring plan, adverse-effect plan, and stopping rule. A global promise of energy or masculinity is not enough.

Consequences

Benefits. Properly selected TRT can change a hypogonadal man’s daily experience. Sexual symptoms can improve. Anemia can correct. Bone density, lean mass, and mood can move in favorable directions. For men whose deficiency has been dismissed because the category is overmarketed, a careful workup can restore function that lifestyle changes alone did not.

The pattern also protects against undertreatment and overtreatment at the same time. A symptomatic man with repeated low values deserves a real workup. A disappointed man with a normal axis, weak sleep, high stress, and a clinic’s promise does not automatically need lifelong testosterone.

Liabilities. TRT raises hematocrit, can raise blood pressure, can worsen acne or edema, can aggravate untreated sleep apnea, suppresses fertility, and exposes household contacts to transferred gel. Some formulations create higher peaks and troughs than others. Some men feel worse, not better, when dose, estradiol, hematocrit, sleep, or expectations are mishandled — symptoms that look like undertreatment can be the wrong delivery, the wrong dose, or the wrong diagnosis.

The trial evidence narrows some fears but does not remove the need for judgment. TRAVERSE is reassuring for major cardiovascular events in a screened, symptomatic, middle-aged and older population using gel under trial conditions. It does not validate supraphysiologic dosing, bodybuilding cycles, under-supervised telemedicine funnels, or TRT for healthy men who want a higher-number identity.

The practical consequence is conservative: diagnose before prescribing, replace rather than escalate, monitor the risks that actually change, protect fertility when it matters, and don’t let masculinity marketing outrank endocrine medicine.

Related Articles

Sources

• U.S. Food and Drug Administration. “Testosterone Information.” Content current February 28, 2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information
• U.S. Food and Drug Administration. “FDA issues class-wide labeling changes for testosterone products.” February 28, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
• U.S. Food and Drug Administration. “FDA Takes Step Forward on Testosterone Therapy for Men.” April 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
• Bhasin, Shalender, Juan P. Brito, Glenn R. Cunningham, et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology & Metabolism 103, no. 5 (2018): 1715-1744. https://doi.org/10.1210/jc.2018-00229
• American Urological Association. “Evaluation and Management of Testosterone Deficiency: AUA Guideline.” Published 2018, reviewed and validity confirmed 2024. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
• Snyder, Peter J., Shalender Bhasin, Glenn R. Cunningham, et al. “Effects of Testosterone Treatment in Older Men.” New England Journal of Medicine 374 (2016): 611-624. https://doi.org/10.1056/NEJMoa1506119
• Lincoff, A. Michael, Shalender Bhasin, L. Michael Flevaris, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” New England Journal of Medicine 389 (2023): 107-117. https://doi.org/10.1056/NEJMoa2215025
• Bhasin, Shalender, Thomas G. Travison, Karol M. Pencina, et al. “Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.” JAMA Network Open 6, no. 12 (2023): e2348692. https://doi.org/10.1001/jamanetworkopen.2023.48692
• Snyder, Peter J., Shalender Bhasin, L. Michael Flevaris, et al. “Testosterone Treatment and Fractures in Men with Hypogonadism.” New England Journal of Medicine 390 (2024): 203-211. https://doi.org/10.1056/NEJMoa2308836
• AUA and ASRM. “Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline.” Amended 2024. https://www.auanet.org/guidelines-and-quality/guidelines/male-infertility

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

Testosterone therapy is prescription endocrine treatment with candidate-specific diagnosis, fertility, prostate, cardiovascular, hematocrit, blood-pressure, sleep-apnea, psychiatric, dermatologic, hepatic, renal, and drug-interaction considerations. It should not be pursued as a self-directed longevity or performance experiment. Eligibility, formulation, dose, monitoring, pausing, dose reduction, referral, discontinuation, and alternative fertility-preserving approaches belong to a qualified clinician who can evaluate the individual patient and jurisdiction.